In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Sarepta Therapeutics, Inc.
(NASDAQ:SRPT), Sally Beauty Holdings, Inc. (NYSE:SBH), Danaher
Corporation (NYSE:DHR), Ellie Mae, Inc. (NYSE:ELLI), BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX), and Akcea Therapeutics, Inc.
(NASDAQ:AKCA), including updated fundamental summaries,
consolidated fiscal reporting, and fully-qualified certified
analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
SRPT DOWNLOAD:
http://Capital-Review.com/register/?so=SRPT SBH DOWNLOAD:
http://Capital-Review.com/register/?so=SBH DHR DOWNLOAD:
http://Capital-Review.com/register/?so=DHR ELLI DOWNLOAD:
http://Capital-Review.com/register/?so=ELLI BCRX DOWNLOAD:
http://Capital-Review.com/register/?so=BCRX AKCA DOWNLOAD:
http://Capital-Review.com/register/?so=AKCA
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Sarepta
Therapeutics, Inc. (NASDAQ:SRPT), Sally Beauty Holdings, Inc.
(NYSE:SBH), Danaher Corporation (NYSE:DHR), Ellie Mae, Inc.
(NYSE:ELLI), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), and
Akcea Therapeutics, Inc. (NASDAQ:AKCA) on a fundamental level and
outlines the overall demand for their products and services in
addition to an in-depth review of the business strategy, management
discussion, and overall direction going forward. Several excerpts
from the recently released reports are available to today's readers
below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed March 4th, 2019. Percentage calculations
are performed after rounding. All amounts in millions (MM), except
per share amounts.
-----------------------------------------
SAREPTA THERAPEUTICS, INC. (SRPT) REPORT
OVERVIEW
Sarepta Therapeutics' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Sarepta Therapeutics reported revenue of
$84.42MM vs $57.28MM (up 47.38%) and analysts estimated basic
earnings per share -$2.09 vs -$0.46. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Sarepta Therapeutics
reported revenue of $301.03MM vs $154.58MM (up 94.74%) and analysts
estimated basic earnings per share -$5.46 vs -$0.86. Analysts
expect earnings to be released on May 2nd, 2019. The report will be
for the fiscal period ending March 31st, 2019. The reported EPS for
the same quarter last year was -$0.44. The estimated EPS forecast
for the next fiscal year is -$1.37 and is expected to report on
February 26th, 2020.
To read the full Sarepta Therapeutics, Inc. (SRPT) report,
download it here:
http://Capital-Review.com/register/?so=SRPT
-----------------------------------------
SALLY BEAUTY HOLDINGS, INC. (SBH) REPORT
OVERVIEW
Sally Beauty's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Sally Beauty reported revenue of $989.45MM
vs $994.96MM (down 0.55%) and analysts estimated basic earnings per
share $0.55 vs $0.65 (down 15.38%). For the twelve months ended
September 30th, 2018 vs September 30th, 2017, Sally Beauty reported
revenue of $3,932.57MM vs $3,938.32MM (down 0.15%) and analysts
estimated basic earnings per share $2.09 vs $1.56 (up 33.97%).
Analysts expect earnings to be released on May 2nd, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.54. The
estimated EPS forecast for the next fiscal year is $2.24 and is
expected to report on November 14th, 2019.
To read the full Sally Beauty Holdings, Inc. (SBH) report,
download it here:
http://Capital-Review.com/register/?so=SBH
-----------------------------------------
DANAHER CORPORATION (DHR) REPORT OVERVIEW
Danaher's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Danaher reported revenue of $5,363.50MM vs
$5,085.70MM (up 5.46%) and analysts estimated basic earnings per
share $1.06 vs $1.23 (down 13.82%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Danaher reported
revenue of $19,893.00MM vs $18,329.70MM (up 8.53%) and analysts
estimated basic earnings per share $3.78 vs $3.58 (up 5.59%).
Analysts expect earnings to be released on April 18th, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.99. The
estimated EPS forecast for the next fiscal year is $5.24 and is
expected to report on February 4th, 2020.
To read the full Danaher Corporation (DHR) report, download it
here:
http://Capital-Review.com/register/?so=DHR
-----------------------------------------
ELLIE MAE, INC. (ELLI) REPORT OVERVIEW
Ellie Mae's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Ellie Mae reported revenue of $116.05MM vs
$112.89MM (up 2.80%) and basic earnings per share $0.00 vs $0.30.
For the twelve months ended December 31st, 2018 vs December 31st,
2017, Ellie Mae reported revenue of $480.27MM vs $417.04MM (up
15.16%) and analysts estimated basic earnings per share $0.66 vs
$1.55 (down 57.42%). Analysts expect earnings to be released on
April 25th, 2019. The report will be for the fiscal period ending
March 31st, 2019. The reported EPS for the same quarter last year
was $0.12.
To read the full Ellie Mae, Inc. (ELLI) report, download it
here:
http://Capital-Review.com/register/?so=ELLI
-----------------------------------------
BIOCRYST PHARMACEUTICALS, INC. (BCRX) REPORT
OVERVIEW
BioCryst Pharmaceuticals' Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, BioCryst Pharmaceuticals reported revenue
of $1.45MM vs $8.76MM (down 83.40%) and analysts estimated basic
earnings per share -$0.28 vs -$0.18. For the twelve months ended
December 31st, 2017 vs December 31st, 2016, BioCryst
Pharmaceuticals reported revenue of $25.19MM vs $26.35MM (down
4.43%) and analysts estimated basic earnings per share -$0.78 vs
-$0.75. Analysts expect earnings to be released on May 14th, 2019.
The report will be for the fiscal period ending March 31st, 2019.
The reported EPS for the same quarter last year was -$0.26. The
estimated EPS forecast for the next fiscal year is -$0.78 and is
expected to report on March 2nd, 2020.
To read the full BioCryst Pharmaceuticals, Inc. (BCRX) report,
download it here:
http://Capital-Review.com/register/?so=BCRX
-----------------------------------------
AKCEA THERAPEUTICS, INC. (AKCA) REPORT
OVERVIEW
Akcea Therapeutics' Recent Financial
Performance
Analysts expect earnings to be released on May
2nd, 2019. The report will be for the fiscal period ending March
31st, 2019. The reported EPS for the same quarter last year was
-$0.44. The estimated EPS forecast for the next fiscal year is
$0.20 and is expected to report on February 25th, 2020.
To read the full Akcea Therapeutics, Inc. (AKCA) report,
download it here:
http://Capital-Review.com/register/?so=AKCA
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
Sally Beauty (NYSE:SBH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sally Beauty (NYSE:SBH)
Historical Stock Chart
From Sep 2023 to Sep 2024